Rancho Mirage, CA

Eisenhower Health

Atrophy

Coronavirus Infections

Shy-Drager Syndrome

Multiple System Atrophy

Waldenstrom Macroglobulinemia

Osteoarthritis

COVID-19

Leronlimab

ONO-2808

Vancomycin

Zanubrutinib

Povidone Iodine

BeiGene

CytoDyn

NYU Langone Health

Ono Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Eisenhower Health | Rancho Mirage, CA

Site insights

Work at this site?

Active trials

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Trial sponsors